NGNE

ANALYST NOTE: NEUROGENE INC. (NGNE) DATE: 2026-06-13

(1) Structural Readiness As of the close on 2026-06-13, NGNE presents a confirmed coil setup. The structural readiness is defined by a conservative entry level of $38.24. The current price is $36.68, representing an extension of -4.1% below the conservative entry. The setup is currently in a "watchlist" state, meaning the breakout signal has fired, but the price is trading within the volatility envelope of the initial move. The ATR at breakout was 6.6% (very high), indicating significant structural quality and volatility at the time of the setup's formation. The current ATR is 7.4% (very high), reflecting elevated volatility today. This high volatility environment suggests that while the setup is active, position sizing must account for the wide price swings inherent in the current market structure. The setup is not "forming" in the sense of a base in place without a breakout; the breakout has occurred, and the stock is now testing the immediate post-breakout range.

(2) The Thesis Layer At this date, NGNE is classified as a TACTICAL, setup-led name. There is no named secular thesis attached to this specific setup in the current evidence base. The conviction for this position must be derived strictly from the quality of the technical setup (the confirmed coil) and the immediate business fundamentals available as of the event date, rather than a broader macro or industry-wide secular trend. The analysis relies on the convergence of a high-quality technical structure with specific, near-term clinical and commercial milestones.

(3) The Business Neurogene Inc. is a clinical-stage biotechnology company focused on developing genetic medicines for rare, severe neurological diseases. Its primary asset is NGN-401, an adeno-associated virus (AAV) delivery gene therapy utilizing EXACT technology, designed for the treatment of Rett syndrome, a condition characterized by substantial neurological and physical impairments.

As of the most recent filings (2026-05-12), the company reports the following operational status:

• Clinical Progress: Approximately 90% of participants in the "Embolden" Phase 1/2 trial have been dosed, with management stating they are "on track to complete dosing in the second quarter of 2026."
• Efficacy Signals: Interim data as of October 30, 2025, showed that four out of five participants with at least 12 months of follow-up met the responder definition of the primary endpoint.
• Safety Profile: The therapy has been "generally well-tolerated" at the 1E15 vg dose, with no cases of hemophagocytic lymphohistiocytosis (HLH) observed in any participant at this dose.
• Regulatory Status: In February 2026, the FDA granted Breakthrough Therapy designation to NGN-401 based on the review of interim efficacy and safety data.
• Commercial Readiness: Management plans to initiate Process Performance Qualification (PPQ) in mid-2026. Crucially, they confirmed that the commercial manufacturing scale is the same as the current clinical manufacturing scale, which removes the need for comparability studies and accelerates the path to commercialization.

(4) The Archetype and Conviction NGNE fits the archetype of a Growth Leader in the context of a clinical-stage biotech with a clear path to commercialization. The company is transitioning from pure R&D to a commercial-ready entity, evidenced by the PPQ initiation and the confirmation of manufacturing scale parity.

• Conviction Factors:
• Evidence Quality: The evidence base is robust, featuring multiple primary filings (E1, E2, E3, E6, E7) and recent news (E16, E17, E18) confirming positive long-term data and regulatory milestones.
• Structural Quality: The ATR at breakout of 6.6% places the setup in the "very high" bucket, historically associated with strong momentum and structural integrity, though it requires careful sizing due to the current 7.4% ATR.
• Rerating Potential: The combination of Breakthrough Therapy designation, positive long-term data, and the removal of comparability studies for manufacturing creates a high-conviction narrative for a potential re-rating as the company approaches commercial launch.
• Setup Readiness: The confirmed coil provides a tactical entry point, though the current price is slightly extended below the conservative entry, suggesting a potential consolidation or re-test of the breakout zone before a sustained move higher.

(5) Invalidating or Strengthening Factors & Gaps

• Strengthening Factors: Successful completion of dosing in Q2 2026 as stated, successful initiation of PPQ in mid-2026, and the absence of new safety signals (specifically HLH) would further validate the commercial readiness.
• Invalidating Factors: A significant delay in the PPQ campaign, the emergence of new safety signals (particularly HLH) in the dosed population, or a failure to meet the primary endpoint in the final analysis would invalidate the commercial thesis.
• Gaps in Evidence: While clinical and operational data is strong, there is no explicit evidence in the provided block regarding the company's cash runway or burn rate as of June 2026, despite the recent capital raise announcements. The impact of the recent $125 million offering (announced June 1, 2026) on the balance sheet is not quantified in the provided text, which is a critical gap for assessing financial sustainability.

PRIVATE ANALYST CALL

Judgment: Speculative Confidence: medium Key evidence: Breakthrough Therapy designation confirmed; 4/5 long-term responders met primary endpoint; PPQ initiation planned for mid-2026 with no comparability studies needed. Key risks: Very high current ATR (7.4%) implies significant volatility and execution risk; recent $125M offering suggests potential dilution or liquidity concerns; no explicit cash runway data provided in evidence. Rating boundary: This is rated Speculative rather than Buy because the current price is extended -4.1% below the conservative entry in a very high volatility environment, and the lack of explicit cash runway data prevents a full conviction on financial sustainability despite the strong clinical data. It would drop to Sell if PPQ is delayed or new safety signals emerge; it would rise to Buy if the price stabilizes above the conservative entry with confirmed cash runway. Sizing hint: Position size should be reduced relative to standard setups due to the very high ATR and the extension below entry. Expected path: Management expects to complete dosing in Q2 2026 and initiate PPQ in mid-2026, with commercial scale confirmed as identical to clinical scale. Expected horizon: 6 to 12 months for the PPQ and commercial scale confirmation to fully play out. Failure mode to watch: Emergence of HLH cases or a significant delay in the PPQ campaign.